Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MANAGEMENT OF IRON-DEFICIENCY IN RENAL ANEMIA - GUIDELINES FOR THE OPTIMAL THERAPEUTIC APPROACH IN ERYTHROPOIETIN-TREATED PATIENTS
Autore:
DRUEKE TB; BARANY P; CAZZOLA M; ESCHBACH JW; GRUTZMACHER P; KALTWASSER JP; MACDOUGALL IC; PIPPARD MJ; SHALDON S; VANWYCK D;
Indirizzi:
HOP NECKER ENFANTS MALAD,INSERM U90,149 RUE SEVRES F-75743 PARIS FRANCE HUDDINGE UNIV HOSP S-14186 HUDDINGE SWEDEN UNIV PAVIA I-27100 PAVIA ITALY MINOR & JAMES MED SEATTLE WA 00000 ST MARKUS HOSP FRANKFURT GERMANY KLINIKUM JWG UNIV FRANKFURT GERMANY UNIV LONDON KINGS COLL HOSP LONDON ENGLAND DULWICH HOSP LONDON SE22 8PT ENGLAND UNIV DUNDEE,NINEWELLS HOSP & MED SCH DUNDEE DD1 9SY SCOTLAND UNIV NIMES HOSP F-30006 NIMES FRANCE UNIV ARIZONA,HLTH SCI CTR TUCSON AZ 00000
Titolo Testata:
Clinical nephrology
fascicolo: 1, volume: 48, anno: 1997,
pagine: 1 - 8
SICI:
0301-0430(1997)48:1<1:MOIIRA>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECOMBINANT-HUMAN-ERYTHROPOIETIN; SERUM TRANSFERRIN RECEPTOR; BONE-MARROW IRON; HEMODIALYSIS-PATIENTS; CHRONIC DISEASE; MAINTENANCE HEMODIALYSIS; MYOCARDIAL-INFARCTION; RHEUMATOID-ARTHRITIS; PERITONEAL-DIALYSIS; CLINICAL-TRIAL;
Keywords:
ERYTHROPOIETIN; IRON DEFICIENCY; IRON SUPPLEMENTATION; RENAL ANEMIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
69
Recensione:
Indirizzi per estratti:
Citazione:
T.B. Drueke et al., "MANAGEMENT OF IRON-DEFICIENCY IN RENAL ANEMIA - GUIDELINES FOR THE OPTIMAL THERAPEUTIC APPROACH IN ERYTHROPOIETIN-TREATED PATIENTS", Clinical nephrology, 48(1), 1997, pp. 1-8

Abstract

Much progress has been made in recent years in the management of anemia associated with chronic renal failure with recombinant human erythropoietin (r-Hu EPO). However, there remains much debate surrounding the diagnosis and treatment of iron deficiency. To ensure that full benefit from erythropoietin therapy is received, most patients require iron supplement during treatment. There are, however, few guidelines for the use of iron therapy. Iron deficiency results in an inadequate response to r-Hu EPO and is the main cause of resistance to this treatment. Oral iron therapy is of limited value in patients receiving r-Hu EPO. Thus, intravenous iron supplementation should be administered only in patients who do not tolerate available intravenous iron preparationsor who are on continuous ambulatory peritoneal dialysis with no evidence of functional iron deficiency. This article provides guidelines for the diagnosis of absolute or functional iron deficiency in patients with renal anemia and suggests treatment schedules for intravenous iron supplementation. We hope that all dialysis patients will be able on this basis to achieve a satisfactory iron status and benefit fully from r-Hu EPO therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 18:09:52